Immuron North American revenue surges by 52% in FY19
July 16, 2019 06:00 ET
|
Immuron Limited
Key Highlights: Immuron FY19 revenue surged by 52% in North America, reaching $1.16M.In the USA, FY19 Travelan® sales exceeded the $1M AUD milestone for the first time and grew by +32% to $1.02M AUD....
Immuron Directors Increase Shareholdings in the Company
June 25, 2019 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, June 25, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company wishes to advise that two of its Directors, Mr Peter...
Immuron to Commence US Non-Deal Institutional Investor Roadshow
June 19, 2019 08:00 ET
|
Immuron Limited
MELBOURNE, Australia, June 19, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Prices Underwritten Public Offering of ADSs
May 23, 2019 21:10 ET
|
Immuron Limited
MELBOURNE, Australia,, May 23, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Announces Proposed Public Offering of ADSs
May 23, 2019 16:45 ET
|
Immuron Limited
MELBOURNE, Australia, May 23, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin...
Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019
April 30, 2019 14:36 ET
|
Immuron Limited
MELBOURNE, Australia, April 30, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
April 17, 2019 09:00 ET
|
Immuron Limited
MELBOURNE, Australia, April 17, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron sales surge by 66% in the Third Quarter of FY19
April 15, 2019 09:00 ET
|
Immuron Limited
Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...
Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile
April 11, 2019 10:00 ET
|
Immuron Limited
C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...
Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea
April 11, 2019 09:00 ET
|
Immuron Limited
Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...